Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marta Bellone"'
Autor:
Caroline Spertini, Bénédicte Baïsse, Marta Bellone, Milica Gikic, Tatiana Smirnova, Olivier Spertini
Publikováno v:
Cancers, Vol 11, Iss 9, p 1253 (2019)
Acute myeloid and lymphoblastic leukemia are poor prognosis hematologic malignancies, which disseminate from the bone marrow into the blood. Blast interactions with selectins expressed by vascular endothelium promote the development of drug resistanc
Externí odkaz:
https://doaj.org/article/229088c5428641e0b0ef6961d592635d
Autor:
Luisa Carrara, Federica Guzzo, Emiliano Cocco, Joyce Varughese, Stefania Bellone, Thomas J. Rutherford, Deborah J. Marshall, Alessandro D. Santin, K. ElSahwi, Peter E. Schwartz, Marta Bellone, Paola Todeschini, Sergio Pecorelli
Publikováno v:
International Journal of Gynecological Cancer. 21:1084-1090
Objective: Uterine serous papillary carcinoma (USPC) is an aggressive variant of endometrial cancer characterized by an innate resistance to chemotherapy and poor prognosis. In this study, we evaluated the expression of αV-integrins in primary USPC
Autor:
Emiliano Cocco, Charles J. Lockwood, Marta Bellone, Ken Yu Lin, Thomas J. Rutherford, Masoud Azodi, Peter E. Schwartz, Natalia Buza, Luisa Carrara, Sergio Pecorelli, Joyce Varughese, Paola Todeschini, Dan-Arin Silasi, Stefania Bellone, Alessandro D. Santin, Renata A. Tassi
Publikováno v:
Clinical & Experimental Metastasis. 28:689-700
We evaluated the expression of tissue factor (TF) in ovarian cancer (EOC) and the potential of hI-con1, an antibody-like molecule targeting TF, as a novel form of therapy against chemotherapy-resistant ovarian disease. We studied the expression of TF
Autor:
Alessandro D. Santin, Emiliano Cocco, Thomas J. Rutherford, Joyce Varughese, Luisa Carrara, Peter E. Schwartz, Paola Todeschini, Sergio Pecorelli, Stefania Bellone, Marta Bellone
Publikováno v:
Gynecologic Oncology. 122:171-177
We evaluated the expression of human trophoblast cell-surface marker (Trop-2) and the potential of hRS7, a humanized monoclonal anti-Trop-2 antibody, as a therapeutic agent against chemotherapy-resistant ovarian disease.Trop-2 expression was evaluate
Autor:
Emiliano Cocco, Alessandro D. Santin, Joyce Varughese, Marta Bellone, Stefania Bellone, Thomas J. Rutherford, Peter E. Schwartz, Maria C. De Leon, Sergio Pecorelli, Paola Todeschini
Publikováno v:
Cancer. 117:3163-3172
BACKGROUND: Uterine serous papillary carcinoma (USPC) was an aggressive and chemotherapy resistant variant of endometrial cancer. The authors evaluated the expression of human trophoblast-cell-surface-marker (Trop-2) and the potential of hRS7, a huma
Autor:
Peter E. Schwartz, Sergio Pecorelli, Dan-Arin Silasi, Alessandro D. Santin, Charles J. Lockwood, Stefania Bellone, Graciela Krikun, Thomas J. Rutherford, Francesca Casagrande, Masoud Azodi, Natalia Buza, Marta Bellone, Paola Todeschini, Christine E. Richter, Zhiwei Hu, Emiliano Cocco
Publikováno v:
British Journal of Cancer
Background: Uterine serous papillary adenocarcinoma (USPC) is a highly aggressive variant of endometrial cancer. Human immuno-conjugate molecule (hI-con1) is an antibody-like molecule targeted against tissue factor (TF), composed of two human Factor
Autor:
Pei Hui, Emiliano Cocco, Peter E. Schwartz, Marilisa Cargnelutti, Sergio Pecorelli, Marta Bellone, K. ElSahwi, Maysa M. Abu-Khalaf, Francesca Casagrande, Masoud Azodi, Dan-Arin Silasi, Natalia Buza, Alessandro D. Santin, Thomas J. Rutherford, Fattaneh A. Tavassoli, Stefania Bellone
Publikováno v:
British Journal of Cancer
Background: Uterine serous papillary adenocarcinoma (USPC) is a rare but highly aggressive variant of endometrial cancer. Pertuzumab is a new humanised monoclonal antibody (mAb) targeting the epidermal growth factor type II receptor (HER2/neu). We ev
Autor:
Peter E. Schwartz, Sergio Pecorelli, Masoud Azodi, Emiliano Cocco, Joyce Varughese, Dan-Arin Silasi, Stefania Bellone, Natalia Buza, Michelle Glasgow, Luisa Carrara, Thomas J. Rutherford, Alessandro D. Santin, Marta Bellone, Paola Todeschini, Charles J. Lockwood
Publikováno v:
BMC Cancer, Vol 11, Iss 1, p 263 (2011)
BMC Cancer
BMC Cancer
Background Cervical cancer continues to be an important worldwide health problem for women. Up to 35% of patients who are diagnosed with and appropriately treated for cervical cancer will recur and treatment results are poor for recurrent disease. Gi
Autor:
Alessandro D. Santin, Masoud Azodi, Marta Bellone, Stefania Bellone, Joyce Varughese, Dan Arin-Silasi, Eric R. Siegel, Francesca Casagrande, Peter E. Schwartz, Sergio Pecorelli, Thomas J. Rutherford, Christine E. Richter, Paola Todeschini, Emiliano Cocco
Epithelial ovarian carcinoma (EOC) remains the cancer with the highest mortality rate among gynecological tumors.1 At the time of diagnosis, ⅔ of patients have advanced disease, and unfortunately, after their initial response to the combination of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25e5b2a0375ba30d05286bbefd95cdb7
http://hdl.handle.net/11379/112916
http://hdl.handle.net/11379/112916
Autor:
Daniel Paik, Emiliano Cocco, Eric E. Siegel, Marta Bellone, Francesca Casagrande, Alessandro D. Santin, Thomas J. Rutherford, Peter E. Schwartz, Stefania Bellone, Christine E. Richter
Publikováno v:
Gynecologic oncology. 119(1)
To compare the in vitro sensitivity/resistance to patupilone versus paclitaxel in uterine serous papillary carcinoma (USPC) with high versus low HER-2/neu expression.Six primary USPC cell lines, half of which overexpress HER-2/neu at a 3+ level, were